Zacks: Brokerages Expect argenx SE – (NASDAQ:ARGX) Will Announce Quarterly Sales of $16.30 Million
Brokerages forecast that argenx SE – (NASDAQ:ARGX) will report $16.30 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for argenx’s earnings, with estimates ranging from $8.96 million to $25.99 million. The business is scheduled to report its next earnings report before the market opens on Thursday, August 1st.
On average, analysts expect that argenx will report full year sales of $87.12 million for the current year, with estimates ranging from $57.68 million to $123.19 million. For the next year, analysts anticipate that the company will post sales of $65.88 million, with estimates ranging from $28.03 million to $129.95 million. Zacks’ sales calculations are an average based on a survey of research firms that cover argenx.
Several equities research analysts have weighed in on the company. Robert W. Baird set a $25.00 target price on Actuant and gave the stock a “buy” rating in a research report on Thursday, June 27th. Stifel Nicolaus set a $154.00 target price on argenx and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Tuesday, July 16th. Finally, Piper Jaffray Companies set a $46.00 target price on Hormel Foods and gave the stock a “buy” rating in a research report on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. argenx presently has an average rating of “Buy” and a consensus target price of $149.91.
NASDAQ ARGX traded up $2.24 during trading hours on Thursday, hitting $142.50. The company had a trading volume of 111,381 shares, compared to its average volume of 114,010. argenx has a fifty-two week low of $63.81 and a fifty-two week high of $150.92. The business has a fifty day moving average of $137.31. The company has a market cap of $4.58 billion, a price-to-earnings ratio of -60.64 and a beta of 1.18.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Why are percentage gainers important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.